Good morning :)
$
₹
Sanara Medtech Inc

Sanara Medtech Inc

SMTI

NASDAQ
Asset Logo

Sanara Medtech Inc

SMTI

NASDAQ
$32.970.52% (+0.17)
$
₹
$32.970.52% (+0.17)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Instruments & Supplies

Small Cap

With a market cap of $301.4M the stock is ranked 3793

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

7.76
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.04
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-29.15%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
0 analyst
Hold
3 analysts
Sell
0 analyst

Price Upside

+6.71%

Earnings Growth

+104.6%

Rev. Growth

+13.07%

See Detailed Forecast

Company Profile

Company Profile

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 6.71% growth, versus a trailing 3-year CAGR of 4.92%.

2026
Current$32.8Baseline
Analyst Target - 1 year
Target$35+6.71%

All values in $

202220232024202520262027$28.27$35.53$42.79Target+6.71%
2026
Current$32.8Baseline
Analyst Target - 1 year
Target$35+6.71%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 13.07% growth, versus a trailing 3-year CAGR of 31.03%.

2025
Current$103.11Baseline
Forecast for Dec 2026
High$116.6+13.07%
Average$116.6+13.07%
Low$116.6+13.07%

All values in $ Million

20212022202320242025202624.1445.8464.9886.67103.11Low+13.07%Average+13.07%High+13.07%
2025
Current$103.11Baseline
Forecast for Dec 2026
High$116.6+13.07%
Average$116.6+13.07%
Low$116.6+13.07%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-4.35Baseline
Forecast for Dec 2026
High$0.2+104.6%
Average$0.2+104.6%
Low$0.2+104.6%

All values in $

202120222023202420252026-1.08-1.39-0.52-1.14-4.35Low+104.6%Average+104.6%High+104.6%
2025
Current$-4.35Baseline
Forecast for Dec 2026
High$0.2+104.6%
Average$0.2+104.6%
Low$0.2+104.6%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

26.3
-30.4
27.5
-1.6
27.7
0.4
28.1
-0.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue18.5320.1521.6726.3023.4325.8326.3327.5427.7928.13
Net Income-1.76-3.50-2.85-1.53-3.52-2.01-30.41-1.600.45-0.45
Net Profit Margin-9.51%-17.38%-13.18%-5.84%-15.04%-7.79%-115.48%-5.84%1.65%-1.60%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Instruments & Supplies

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Sanara Medtech Inc -7.76-
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SMTI with any stock or ETF
Compare SMTI with any stock or ETF
Comparing from
SMTI
ABT
DHR
Loading...

Frequently asked questions

  1. Sanara Medtech Inc (SMTI) share price today is $32.97 as of October 27, 2026 at 1:29 AM IST. The stock touched a day high of $33.00 and a day low of $32.42.

  2. Sanara Medtech Inc stock trades on NASDAQ under the ticker symbol SMTI.

  3. Sanara Medtech Inc's market capitalization is $301.36M as of October 27, 2026 at 1:29 AM IST.

  4. Sanara Medtech Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Sanara Medtech Inc's price-to-book (P/B) ratio is 7.76 as of October 26, 2026.

  6. Yes, You can buy Sanara Medtech Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Sanara Medtech Inc shares in three steps: 1. Search Sanara Medtech Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Sanara Medtech Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Sanara Medtech Inc (SMTI) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3032 shares at the current price of $32.97.

Loading...